Tamari Roni, Castro-Malaspina Hugo
Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
Best Pract Res Clin Haematol. 2015 Mar;28(1):43-54. doi: 10.1016/j.beha.2014.11.006. Epub 2014 Dec 4.
Allogeneic hematopoietic stem cell transplantation is the only curative treatment for myelodysplastic syndrome. Major improvements in the field of allogeneic stem cell transplantation have made it a better tolerated treatment that can be offered to older patients and patients with co-morbidities. However, treatment related toxicities, graft versus host disease, infectious complications and relapse remain major problems post transplant. With better understanding of disease biology and prognosis and with different types of conditioning regimens as well as different graft sources, a transplant strategy should be tailored to the individual host to maximize the benefits of this procedure.
异基因造血干细胞移植是骨髓增生异常综合征唯一的治愈性治疗方法。异基因干细胞移植领域的重大进展使其成为一种耐受性更好的治疗方法，可用于老年患者和合并症患者。然而，治疗相关毒性、移植物抗宿主病、感染并发症和复发仍然是移植后的主要问题。随着对疾病生物学和预后的更好理解，以及不同类型的预处理方案和不同的移植物来源，应根据个体宿主量身定制移植策略，以最大限度地提高该治疗方法的益处。
